文献速递慢阻肺呼吸道感染

阿奇霉素预防慢阻肺急性加重的获益-危害分析

Benefit-harm analysis of azithromycin for the prevention of acute exacerbations of chronic obstructive pulmonary disease.
PubMed 文献 · Thorax · 2021-11-26

研究采用概率马尔可夫模型模拟慢阻肺20年病程,评估低剂量口服阿奇霉素预防急性加重的净获益。结果显示,有近期加重史的患者每100人20年净获得17.9个QALY,频繁加重者增至21.8个QALY,而无中重度加重史者无净获益。

要点

  • 有近期加重史的慢阻肺患者使用阿奇霉素可获得净QALY获益。
  • 频繁加重者获益更大,每100人20年净增21.8个QALY。
  • 无中重度加重史者使用阿奇霉素无净获益。

核心结论

  • 长期阿奇霉素治疗对近期有加重史的慢阻肺患者有净获益,对频繁加重者获益更大。

研究设计与样本

  • 研究构建了慢阻肺概率马尔可夫模型,模拟20年病程,模型参数来自文献和专门数据分析。

主要发现

  • 有加重史患者每100人20年净获得17.9个QALY,概率为99.8%。
  • 频繁加重者每100人20年净获得21.8个QALY,概率为99.9%。
  • 无中重度加重史者未显示净获益。
  • 结果在一系列敏感性、情景和阈值分析中稳健。

关键数值与推荐

  • 阿奇霉素的获益建模为加重率降低,同时考虑心血管事件、听力损失、胃肠道症状和抗菌素耐药等不良事件。
  • 所有结局均赋予健康效用权重以估算QALY净变化。

临床怎么用

  • 对于近期有加重史的慢阻肺患者,可考虑长期低剂量阿奇霉素预防急性加重。
  • 频繁加重者可能从阿奇霉素治疗中获得更大净获益。
  • 无中重度加重史的患者不建议使用阿奇霉素预防。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Low-dose oral azithromycin therapy is recommended as a preventive treatment for acute exacerbations of COPD. However, the overall benefit-harm balance of this treatment has not been well studied. METHODS: A probabilistic Markov model of COPD was created to simulate the course of COPD over 20 years. The model was populated with evidence from the literature and dedicated data analysis. The benefit of azithromycin was modelled as a reduction in exacerbation rates. Adverse events, including cardiovascular events, hearing loss, gastrointestinal symptoms and antimicrobial resistance (leading to a gradual decline in the effectiveness of azithromycin), were considered. All outcomes were assigned a health-related utility weight to estimate the overall net change in the quality-adjusted life year (QALY) associated with the use of azithromycin. RESULTS: In patients with a positive exacerbation history, azithromycin resulted in a net QALY gain of 17.9 per 100 patients (99.8% probability of expected QALY gain) over 20 years. The net benefit increased to 21.8 QALYs per 100 patients (99.9% probability of expected QALY gain) among the 'frequent exacerbator' subgroup. Azithromycin was not net beneficial among those without any moderate/severe exacerbations in the previous year. Findings were robust against series of sensitivity, scenario and threshold analyses. CONCLUSIONS: Long-term therapy with azithromycin confers a net benefit to ex-smoker patients with COPD with a recent history of exacerbations and an even larger benefit to those who are frequent exacerbators.

来源:Thorax,查看原文。版权归原作者所有。

引用

  1. Ahmadian, Sin, Lynd, et al. Benefit-harm analysis of azithromycin for the prevention of acute exacerbations of chronic obstructive pulmonary disease. Thorax. 2021. PMID: 34836921. doi:10.1136/thoraxjnl-2021-217962

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。